Friday - May 9, 2025
YOKNEAM, Israel, May 17, 2023 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, today announced that InMode will participate at the following investor conferences and events:
BNPP Exane Aesthetics Day
Presenters: Moshe Mizrahy, Chief Executive Officer, Yair Malca, Chief Financial Officer and Spero Theodorou MD, Chief Medical Officer
Format: Virtual fireside chat moderated by Navann Ty, Lead Equity Analyst
When: Tuesday, May 23 at 10:00 am ET
A replay of webcast of the presentation can be accessed here.
Barclays West Coast Bus Trip
Presenters: Yair Malca, Chief Financial Officer and Spero Theodorou MD, Chief Medical Officer
Format: In-person investor bus tour at InMode's North American headquarters
Location: Irvine, CA
When: Tuesday, May 23 at 10:30 am PT
Jefferies Healthcare Conference
Presenters: Yair Malca, Chief Financial Officer
Format: In-person fireside chat moderated by Matt Taylor, Equity Analyst and one-on-one meetings
Location: NYC, NY
When: Wednesday, June 7 at 1:00 pm ET
A live webcast of the presentation can be accessed here.
About InMode
InMode is a leading global provider of innovative medical technologies. InMode develops, manufactures, and markets devices harnessing novel radiofrequency ("RF") technology. InMode strives to enable new emerging surgical procedures as well as improve existing treatments. InMode has leveraged its medically accepted minimally-invasive RF technologies to offer a comprehensive line of products across several categories for plastic surgery, gynecology, dermatology, otolaryngology, and ophthalmology. For more information about InMode and its wide array of medical technologies, visit www.inmodemd.com.
Investor Relations Contact:
Miri Segal-Scharia
MS-IR LLC
ir@inmodemd.com
917-607-8654
Last Trade: | US$14.45 |
Daily Change: | 0.22 1.55 |
Daily Volume: | 1,333,453 |
Market Cap: | US$1.100B |
April 28, 2025 March 03, 2025 February 04, 2025 |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MOREEnd of content
No more pages to load